Previous close | 206.45 |
Open | 209.06 |
Bid | 194.69 x 800 |
Ask | 213.51 x 800 |
Day's range | 204.51 - 210.98 |
52-week range | 198.11 - 285.61 |
Volume | |
Avg. volume | 1,162,923 |
Market cap | 39.46B |
Beta (5Y monthly) | 1.46 |
PE ratio (TTM) | 37.33 |
EPS (TTM) | 5.54 |
Earnings date | 25 Jul 2022 - 29 Jul 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 263.13 |
IQVIA (IQV) rides on a solid healthcare-specific global IT infrastructure and analytics-driven clinical development skills. However, a weak balance sheet is worrisome.
Mastercard's (MA) first-quarter results reflect improved GDV and switched transactions, partly offset by higher operating expenses.
At this time, I would like to welcome everyone to the IQVIA first quarter 2022 earnings conference call. With me today are Ari Bousbib, chairman and chief executive officer; Ron Bruehlman, executive vice president and chief financial officer; Eric Sherbet, executive vice president and general counsel; Mike Fedock, senior vice president, financial planning and analysis; and Bryan Stengel, associate director, investor relations.